e-Therapeutics plc Total Voting Rights (7385H)

TIDMETX

RNS Number : 7385H

e-Therapeutics plc

31 July 2023

e-therapeutics plc

("e-therapeutics" or the "Company")

Total Voting Rights

London, UK, 31 July 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces that in accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company has 582,694,162 ordinary shares of 0.1 pence each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 582,694,162.

The above figure of 582,694,162 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company.

Enquiries:

 
    e-therapeutics plc 
    Ali Mortazavi, CEO                             Tel: +44 (0)20 4551 
     Timothy Bretherton, Director of Finance        8888 
     and Operations                                 www.etherapeutics.co.uk 
------------------------------------------------  ------------------------- 
 
     SP Angel Corporate Finance LLP                Tel: +44(0)20 3470 
                                                    0470 
    Nominated Adviser and Broker 
    Matthew Johnson/Harry Davies-Ball (Corporate 
     Finance) 
    Vadim Alexandre/Rob Rees (Corporate Broking) 
------------------------------------------------  -------------------------

About e-therapeutics plc

e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic.

ETX's proprietary HepNetTM platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery. This approach explicitly considers the true complexity of biology to make more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data resource. The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.

GalOmicTM, ETX's proprietary RNAi platform, enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by HepNetTM. The focus on hepatocytes offers the opportunity to tackle a wide variety of diseases. The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalOmicTM constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.

The Company is progressing a pipeline of first-in-class preclinical RNAi candidates across several high unmet medical needs in cardiometabolic indications and targeting promising hepatocyte-expressed targets with effects in other disease areas. ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.

The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. E-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRZZGFNLMNGFZG

(END) Dow Jones Newswires

July 31, 2023 11:30 ET (15:30 GMT)

E-therapeutics (LSE:ETX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024